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Abstract: Recent advances in genomic medicine have led to the availability of genomic tests that have
the potential to improve population health, yet the process for obtaining these tests and getting them
reimbursed by insurers has not been described. The objective of this study was to describe the process
of ordering pharmacogenomic tests by interviewing providers, patients, and laboratories about
cancer-related pharmacogenomic tests. We interviewed patients who were prescribed, providers
who prescribed medications that should be guided by pharmacogenomic testing, and individuals
from diagnostic laboratories. A total of 10 providers, 16 patients, and eight diagnostic laboratories
described logistical and insurance issues relating to ordering and receiving pharmacogenomic tests
and medications. We found that the process of ordering pharmacogenomic tests is time-consuming,
expensive, and complex. Ordering pharmacogenomic tests is quite different across institutions.
Even in the same institution, multiple providers can order the test. Once the provider places the order
for the pharmacogenomic test, the laboratory receives the request and usually begins testing without
knowing how the test will be paid for. Next, the laboratory completes the pharmacogenomic testing
and the results of the tests are reported to providers, patients, or placed directly in the medical record.
In conclusion, processes related to ordering and obtaining insurance coverage for pharmacogenomic
tests varies greatly across institutions and is time-consuming.
Keywords: pharmacogenomics; implementation; cancer
1. Introduction
Genomic medicine is exploding with discoveries that could improve cancer care, and many
pharmacogenomic tests are becoming available for use in clinical practice [1,2]. Nevertheless,
translation of new genomic technologies into clinical practice has been slower than hoped [3,4]. As of
January 2018, 54,334 tests for 10,999 conditions and 16,419 genes were available [5]. The U.S. Food and
Drug Administration (FDA) has included pharmacogenomic information in the drug labels of more
than 100 drugs, with 31% being oncology therapy [6]. For example, clinical guidelines recommend that
patients with early stage breast cancer with overexpression of human epidermal growth factor-like
receptor No 2 (HER-2) receive trastuzumab [7], and erlotinib is recommended for epidermal growth
factor receptor (EGFR) mutation positive nonsquamous non-small cell lung cancer [8]. Even with FDA
recommendations for use of pharmacogenomic testing for these and other drugs, insurance companies
can choose whether or not to cover them [1] and for whom. While pharmacogenomic tests for cancer
are available, they are underutilized in clinical care [9,10].
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It is critical to determine factors that could be related to this underutilization. Previous studies
have examined the adoption of pharmacogenomic testing by providers [11] and attitudes of providers
towards testing and subsequent decision-making for patients [12,13]. Our previous study of patients’
and providers’ views on access to cancer-related pharmacogenomic tests found that the process
could be time-consuming and complex [14]. Nevertheless, no studies have examined the processes
for ordering and paying for pharmacogenomic tests in the context of cancer care. The objective of
this study was to explore the process of ordering and paying for pharmacogenomic tests through
interviews with providers, patients, and laboratories in order to identify challenges or strategies that
could facilitate access.
2. Materials and Methods
2.1. Overall Design
This qualitative study was approved by the Institutional Review Board at Harvard Pilgrim Health
Care (HPHC). Provider, patient, and laboratory participants were given a $25 gift card for their time
and appreciation of their participation.
2.2. Sampling
We used insurance claims data from HPHC, a regional health plan covering about 1 million
members from New England. Based on HPHC claims data from 1 May 2013 to 30 April 2014,
we identified 126 providers who had prescribed any of a selected list of cancer targeted therapies
that could be informed by pharmacogenomic tests in accordance with clinical guidelines (Table 1).
Details of our sampling process are described in a previous study [14]. Briefly, we mailed invitation
letters to 126 providers and 261 patients, asking them to call a toll-free line or email if they were
interested in participating in a telephone interview. Through our provider interviews, we learned that
diagnostic laboratories play a major role in the process of access and reimbursement. Representatives
from key laboratories that manufacture and run pharmacogenomic testing were recruited using
snowball sampling. We identified and contacted 12 diagnostic lab employees who had experience with
pharmacogenomic testing, either in a commercial or academic lab setting.
Table 1. Interview participants and demographic information.
Stakeholder Group
Provider 10
Patient 16
Diagnostic Lab 8
Sex
Female 20
Male 14
Ethnicity/Race
Asian 4
White 29
More than One Race 1
Age
30–39 years 4
40–49 years 8
50–59 years 14
Over 60 years 8
Cancer Type * Provider Patient
Breast 3 5
Colorectal 2 0
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Table 1. Cont.
Stakeholder Group
Non-Small-Cell Lung Cancer 5 3
Prostate 0 2
Leukemia 3 4
Other 4 5
Drugˆ
Cetuximab 1 2
Panitumumab 0 0
Trastuzumab 1 5
Pertuzumab 1 0
Ado-Trastuzumab Emtansine 1 0
Lapatinib 1 0
Trametinib 2 0
Dabrafenib 2 3
Crizotinib 5 5
Dasatinib 3 2
Imatinib 2 0
Bosutinib 3 0
* Cancer diagnosis that patient received or provider diagnosed that led to inclusion in the study. ˆ Cancer drug that
patient received or provider diagnosed that led to inclusion in the study.
2.3. Instrument and Data Collection
Once selected, provider and patient interviews were conducted via telephone by two of the
study’s investigators, Wu and Ceccarelli. We asked questions in four main areas: (1) the process for
deciding to order this particular medicine and whether any pharmacogenomic tests were ordered
before starting the medication; (2) factors influencing the decision to order or not order the test and to
review the clinical implementation process for the test; (3) whether the provider discussed ordering the
pharmacogenomic test with the patients and to what extent the patient was involved in the decision to
order the test; and (4) challenges and difficulties in obtaining the pharmacogenomic test, whether prior
authorizations were requested, whether genetic testing was ever denied, and how health insurance
coverage affects use of pharmacogenomic tests.
Interviews with representatives of diagnostic labs were conducted via telephone by two of the
study’s investigators, Lu and Loomer. Questions focused on similar content to provider and patient
interviews: (1) the process of conducting and billing for pharmacogenomic tests in the context of
cancer; (2) factors that influenced communication with patients, providers, and insurers; (3) how
providers or insurers were involved in the testing or billing process, at any stage; and (4) challenges in
conducting and billing tests including prior authorizations and denials of coverage. The interview
questions served as a guide, and the interviewer had discretion in phrasing, using probes, and posing
additional questions during the interview. Interviews lasted approximately 30 to 45 min each.
2.4. Analysis
The initial coding scheme was developed by the study team using the interview questions as
a starting point. While provider transcripts were analyzed by Wu and Ceccarelli, patient and lab
transcripts were analyzed by Wu and Loomer. Themes were identified while building the codebook.
Findings were circulated to the study team, discrepancies discussed until agreed upon, omissions
identified, and the codebook and coding scheme revised and finalized. Transcripts were again coded
using the finalized codebook and coding scheme.
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3. Results
Table 1 provides an overview of interview participants. Based on results of the interviews of
the providers, patients, and representatives of laboratories, we developed a diagram of the processes
involved in ordering and paying for pharmacogenomic tests (Figure 1). After a patient receives
a diagnosis, a provider orders a pharmacogenomic test. Prior to ordering the test, providers may
determine if prior authorization is needed. Prior authorization may require the provider to provide
justification; the insurer may review clinical utility policies to decide on approval. Once the provider
orders the test, the lab receives the order. Sometimes the lab submits the prior authorization to the
insurer. The lab usually starts the testing process immediately after receiving the order. The lab then
completes the test and reports results to the provider. Once the lab test is completed, the lab bills the
insurer. Sometimes the patient pays for the test partially or fully, sometimes the insurer covers the
costs of the test fully, and sometimes the laboratory absorbs the costs of the test if the insurer does not
pay and the laboratory has conducted the testing.
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Figure 1. Schematic of the clinical implementation process for pharmacogenomic tests.
3.1. Challenges, Adaptations, Impact, and Recommendations
Interviewees reported on challenges, adaptations, impact, and recommendations for each stage in
the ordering process of pharmacogenomic testing (Table 2). The stages in the process include ordering
the tests, the analysis of the samples by the laboratory, the reporting of results by the laboratory,
and payment for the tests.
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Table 2. Challenges, adaptations, impact, and recommendations on the pharmacogenomic
testing process.
Theme
Category Subtheme Quotation Stakeholders
Ordering
Challenge
Clinical implementation
process is time-consuming,
variable
I have to be telling them I’m sorry. I submitted the
prior authorization, I’m waiting for the insurance,
I’m sure it will be approved just give me another few
days and I’ll get back to you.
Providers, Labs
Ordering
Challenge
No set process for
ordering; no designated
staff; time consuming
Providers may not have
needed expertise to select
the correct test
I think the ordering physicians are sometimes
confused and I think the patients are
sometimes confused.
Providers, Labs
Ordering
Challenge
Multiple labs offering
sequencing
There are a lot of labs out there that now are offering
something in this gene sequencing area. It seems
like every day another lab pops up and one has a
specific test for colon cancer and one has a specific
test for breast cancer, another for pancreatic, another
has this, another has that. I think it’s confusing
to clinicians.
Labs
Ordering
Challenge
Patients do not know if
tests will be paid for
I think it’s confusing to patients at times because
they don’t know if it’s going to be paid for. Providers
Ordering
Adaptation
Resources made available
for all parties to
understand complex field
And we have a lot of technical resources, both fields
based and available on the phone, to discuss test
choices with clinicians, to discuss results with
clinicians, to say— if they have questions, if they
get answer 1 back, if they should do another step, if I
should look at something else. There are a lot of
resources available. I think that that’s the way this
area is built; to be very, very consultative.
Labs
Ordering
Impact
Panel tests may be
unnecessarily ordered
Ordering physicians are grabbing a lot of
information and the thought is that patients will
unnecessarily act upon some of this genetic
information that never may manifest itself.
Labs
Ordering
Recommendation
Insurer policies need to be
clinically relevant
So recognizing that the payers couldn’t come up
with it themselves, and if they came up with it
themselves it probably wouldn’t be in line with what
we consider to be clinically relevant.
Labs
Ordering
Recommendation
Need definitions and to
establish clinical utility
Along with that comes proof of clinical utility and I
think many medical directors view genetic testing
currently in oncology as—outside of the danger of
EGFR*, BRAF, KRAS, apart from the standard of
care tests, larger panels or next gen sequencing,
they don’t see the levels of evidence that they see for
other covered services. And so that’s a challenge.
Labs
Ordering
Recommendation
Need better information
technology support
The two big [challenges] would be IT support and
informatics support. Labs
Lab Analysis of
Samples
Challenge
Unable to stop request
once made
Unfortunately, because of how molecular pathology
works—and a lot of our payer’s struggle to
understand this—is it’s not like giving a drug . . .
there’s not really an easy way to stop the test [if
prior authorization is not approved]. So it’s not the
type of thing where we can call the payer and say
this is what we’re doing, and if they say it’s not
approved, we can’t really do anything about it. We
can’t stop it, it’s already kind of in progress. From
our perspective, it’s the first step of getting that
authorization because right now we’re not getting
that authorization and having to eat the cost if it
comes back no prior authorization.
Labs
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Table 2. Cont.
Theme
Category Subtheme Quotation Stakeholders
Lab Analysis of
Samples
Impact
Lab sometimes reports test
results before knowing
who will pay
Many times we will report out the test results before
we can present what the patients out-of-pocket costs
will be. If we determine that there are no prior
authorizations, it’s a small window of time, let’s say
five business days, to go back and get that because
you never want the sample to go bad.
Labs
Lab Analysis of
Samples
Impact
Lab does not report
findings because test was
not paid for
Well once it’s [testing] done, it’s done. If it’s done in
the middle, it happens very rarely I have to say—
But once in a while it does and honestly, we just
kind of finish it off but then we don’t report it. So
that’s kind of what we do because it’s hard to stop in
the middle.
Labs
Lab Analysis of
Samples
Adaptation
Labs starting to ask
patients to sign a waiver
that they will cover the
costs if the insurer does not
we may start asking the patients to sign a waiver if
we can’t get approval for it just because . . . there
isn’t enough evidence where we would be able to
confidently say we can for sure get this covered.
Labs
Lab Analysis of
Samples
Adaptation
Phone calls, try to get PA
If [prior authorization is not approved], the very
next morning we make some phone calls to see,
before the test-prep for the test can start but the test
actually isn’t in the rigors of being done. So we can
stop, make some phone calls and try to get the prior
auth. or try to get the clinicians office to get the
prior auth. for us.
Labs
Lab Analysis of
Samples
Adaptation
Price degradation
Absolutely, it is a competitive market and we use
price degradation as more and more of these labs
jump in, especially the cancer piece. If you see that
price going down and down and down. . . . We
negotiate a flat rate and that flat rate is definitely
market competitive.
Labs
Lab Analysis of
Samples
Adaptation
Negotiate with insurers
We are, in some cases, trying to negotiate with
payers such that we have an availability to have a
little gap so that it’s not just prior authorizations.
. . . We have been able to negotiate with some payers
recently, this window [before sample goes bad] so
it’s kind of prior and post-authorization.
Labs
Reporting of
Results
Challenge
Clinical utility of tests
difficult to assess; Difficult
to determine whether
results are being used
appropriately
The other aspect that makes that area more
challenging is that the test itself typically isn’t the
intervention that causes the benefit, it’s typically
some therapy that that test informs or doesn’t
inform. So if it’s a surgical procedure or a drug, it’s
relatively straightforward—does that drug or
procedure have the intended effect. For the
diagnostic test, it’s both: does that test measure
what it says it measures and then second, does
measuring what it says it measures actually matter
in therapy? And that gets much grittier.
Provider
Reporting of
Results
Challenge
Provider may not have
expertise interpreting
results genetic tests
So a better understanding on behalf of the providers
so that they understand when we give them a result,
that’s positive or negative, what does that
really mean.
Labs
Reporting of
Results
Challenge
Patients are given results
without context or
education
I think that’s a very concerning area in general with
patient portals because they have access to all sorts
of information that they have to understand without
any context or background.
Labs
Reporting of
Results
Adaptation
Labs attempt to stay on top
of technology
[Our lab] is trying to, because we are connected to
so many doctors, we are trying to stay up with all
the technology that’s out there.
Labs
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Table 2. Cont.
Theme
Category Subtheme Quotation Stakeholders
Reporting of
Results
Adaptation
Labs trying to inform
insurers
We have a spreadsheet full of some of the best papers
out there supporting each gene for each indication so
that is something that so [some] payers . . . relied on
our clinical experts to help create their medical
policy and so we have used our approach to
determine nationally, or regionally rather, what is
clinically appropriate.
Labs
Reporting of
Results
Adaptation
Work with doctors to
interpret results and have
meaningful impact on
treatment decision
And so we’ve really spent a lot of our recent efforts
over the last two years or so in trying to create that
bridge from results the doctors gets to the actual
treatment of the patient.
Labs
Reporting of
Results
Recommendation
Patients and providers
given better understanding
of testing/results
It would help if more of the patients— more of the
people who ordered the tests really understood what
the test can and cannot tell them. So a better
understanding on behalf of the providers so that
they understand when we give them a result that’s
positive, or negative, what does that really mean.
Payment for tests
Challenge
Insurance policies vary,
including in requirements
for prior authorization;
cost is unknown
More and more plans are requiring prior
authorization for genetic testing to be able to get a
handle on what they’re paying for and so we see the
health plans requiring PA, more and more prior
authorizations, not just for cancer but for
genetic testing.
Lab
Payment for tests
Characteristic
If insurer does not cover,
patient covers or
laboratory absorbs cost
The biggest denials we’re seeing today are for our
payers that are now requiring prior authorization.
Unfortunately—well fortunately, depends on who
you ask—those come back as provider liable not
patient liable. So we have to just eat the cost of those.
We will try to appeal them sometimes, depending
upon the volume. But for the most part, there’s not
much we can do about those. [ . . . ] So, if the payer
denies it, patient liable, we would bill the patient.
Lab
Payment for tests
Challenge
Challenge: Coding is
confusing
And then these panel codes came along and it kind
of mucked up the water because panel codes are
described as a next generation sequencing test of 5
to 50 genes, a next gen sequencing test of 50 or
more genes which seems to imply more method than
the specific gene. . . . So depending upon which
institute you ask, people have different
interpretations of that.
Labs
Payment for tests
Adaptation
Ask patients to sign waiver
that they will cover costs if
insurer does not
So for commercial insurance, we will have them
sign a waiver. We aren’t doing it yet today but
again, everything we’re billing today, we have done
extensive research to make sure that it meets a
certain level of clinical evidence.
Labs
Payment for tests
Adaptation
Vendor directly charges
insurance
[When] the vendor then charges directly the
insurance and bypasses the hospital getting a bill,
that has been very good for pathology because they
have a less of a headache of keeping track of
reimbursements but it also has made it a little bit
less clear for the providers when a patient runs into
a problem with insurance coverage because we
basically don’t get those bills within our system.
Providers
Payment for tests
Adaptation
Patients can cancel test to
not incur cost
So there is a point in time, if the results haven’t been
reported, to say to the patient, this is your OOP
cost. At that point, the patient will say I don’t want
it. Cancel the test. And so we will cancel the test. I
don’t think we give them the option. I would have to
check on that.
Labs
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Table 2. Cont.
Theme
Category Subtheme Quotation Stakeholders
Payment for tests
Adaptation
Patients can cancel test to
not incur cost
So there is a point in time, if the results haven’t been
reported, to say to the patient, this is your OOP
cost. At that point, the patient will say I don’t want
it. Cancel the test. And so we will cancel the test. I
don’t think we give them the option. I would have to
check on that.
Labs
Payment for tests
Adaptation
Compile data and discuss
with insurer
If I determine we have a payer that’s rejecting a lot
of X, Y, Z test(s) and it costs me a lot to do, and
they’re paying for 10% of them and we get 90% of
them, then I compile that data. And then I would go
back to the plan and have a conversation. And I say,
let’s talk about this, let’s figure it out. Because one
way or another, you have to figure out a way to get
paid. Whether that’s by you or by the patient.
Labs
Payment for tests
Adaptation Appeal
So that appeals group will look to the literature that
we’ve identified in conjunction with the clinical
team. They may reach out to the doctor that
specifically was treating that patient for further
support of why it was clinically relevant. And then
they will work with them and try and write an
appeal to the insurance company.
Labs
Payment for tests
Recommendation Concise, transparent forms
I just wish they would make it a little easier to fill
out the forms without having to go back and forth
and back and forth.
Providers
Payment for tests
Recommendation
Prior authorization
procedures should be easy
to find
So if all the insurance companies could get
standardized in terms of the form, that would make
it so much easier for the patients and for us. Some
what you do is submit online, some you have to fill
out a form and then you have to fax it, it’s even
that varies.
Labs
Payment for tests
Recommendation Real-time adjudication
We’ve rolled out with some payers in some regions
and with a couple of the national payers, that is
called real time adjudication which would do that so
it doesn’t charge the patient. It does that computer
connection, it pings the payer system right from
before the patient gets their blood draws . . . So the
real time adjudication is going to be the answer
because then it will be specific for me as a patient,
versus you as a patient.
Labs
Payment for tests
Recommendation
Universal coverage
documentation
[Some] groups are really pushing for a national
coverage document instead of these local coverage
determinations. But people are tentative about that
though because there is so much variation and we
would want to make sure they went with one that
was in agreement with our assessment versus some
of them that are not in agreement with what we
consider clinically relevant.
Labs
3.1.1. Ordering Tests
Providers reported that the clinical implementation process for pharmacogenomic testing is
time-consuming and variable for each insurer and patient. One provider stated, “It’s this waiting
game for [the patient]”. Another challenge mentioned that it was the providers not having the
expertise to order the tests, particularly panel tests. Providers noted that molecular pathology
is confusing. Moreover, with so many new sequencing tests becoming available, “it is confusing
to clinicians”. Some laboratories felt that larger, panel tests are sometimes ordered when they are
unnecessary. A laboratory representative also stated that it is difficult to assess whether results of tests
are used appropriately.
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Laboratory representatives also believed that patients sometimes did not know whether the
tests would be covered by insurers. Furthermore, providers stated that insurance requirements for
coverage should be transparent and easy to find. Another provider expressed, “you see so many
different patients with so many different insurance plans and you know different prescription plans
and you don’t know what’s covered, what’s not and a large part of our day is spent you know figuring
out what’s covered what’s not, what needs a prior authorization, what doesn’t, what the insurance
will cover”.
One provider stated that their clinical group has adapted to the confusion around ordering and
payment of pharmacogenomic tests by making resources about the process and costs available for all
parties to help understand this complex field. However, laboratory representatives felt that sometimes
providers order pharmacogenomic tests that are not needed.
Interviewees offered multiple suggestions for improving the clinical implementation process
for pharmacogenomic tests. First, laboratory representatives felt that policies for pharmacogenomic
testing could govern their use instead of insurers’ prior authorization requirements: “The benefit of
developing a good medical policy that’s very clear and takes a long time is that it precludes the need
for the complex and expensive preauthorization process”. Secondly, laboratory representatives stated
that clinical utility needs to be established. One representative stated, “So we’re in a position now
where we need to come to some form of consensus, certainly publish more to support doing panels in
cancer patients and then that should be a covered service. It goes hand in hand with getting paid and
having insurance pay for it, is developing clinical utility”. Third, providers felt that streamlining the
process for ordering pharmacogenomic tests would be beneficial and would help prevent stress for
patients as “They’re dealing with a very difficult diagnosis and it’s so stressful as it is and then to you
know have patients be told well you know your insurance might not cover this or we have to find an
alternative is really tough to tell people as a provider”.
3.1.2. Laboratory Analysis of Samples
Laboratory representatives stated that most laboratories start testing as soon as they receive
samples in order to avoid delaying patient care. One laboratory representative stated, “within a day
or so, ya’ know FedEx drops off the sample, whether that is blood and/or saliva, and the test is—we
start to run the test immediately as long as it is a good sample.” Another laboratory representative
stated, “We never want to put the patient in a bad place. We generally proceed with the test and
end up not getting paid”. In addition, laboratory representatives noted that the process of testing is
different than the process of ordering medications, although similar processes are adopted for both.
For example, once laboratories start the process of pharmacogenomic testing, it is difficult to stop; thus,
tests are sometimes run without knowledge of where the payment will come from, with the result
that costs may end up being absorbed by the laboratory or paid for by the patient. In order to adapt,
laboratories are starting to request that patients sign an agreement to cover the costs if the insurers
will not. Laboratories also work hard to obtain prior authorizations and try to avoid negotiating
competitive flat rates.
3.1.3. Reporting of Results
Once laboratories report the results of a test, providers and patients sometimes do not know what
to do with the results. Providers noted that sometimes the clinical utility of tests is not known to them,
making it difficult to know how to interpret test results even if there is promise that a test result will result
in improved response to treatment. One provider stated, “In today’s day and age we actually have drugs
that target, that are actually useful in that situation [of a positive pharmacogenomic test] so finding that
information today would actually affect how we treat a patient . . . . We can say that there are treatments that
may improve your outcomes but are not proven to”. Laboratories have adapted by working with doctors
to interpret results with one representative stating, “We are trying to sort of pull the patient and doctor
through to the other side to make the results of our testing even more useful”. Laboratory representatives
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emphasized that providers need to understand how to interpret results with one representative stating,
“They’re the ones talking to patients and if they’re telling the patients ‘this is why I’m sending the test’ and
that’s not why they’re sending the test, there’s a lot of confusion on the patient’s behalf”.
Laboratories have also worked to try to inform insurers of the utility of tests. One representative
stated, “We can share with payers if they’re asking about a specific gene, why we’re running that test,
we have a lot of references already pulled together to share”. The reason for sharing information is
“a lot of the health plans don’t have the internal expertise to know how to create an internal policy on
molecular pathology”. Another laboratory representative stated they have worked to make the results
of testing more useful: “And so we’ve really spent a lot of our recent efforts over the last two years or
so in trying to create that bridge from the results the doctor gets to the actual treatment of the patient”.
3.1.4. Payment for Tests
Multiple providers and laboratory representatives expressed that insurance policies and
requirements for prior authorization vary across insurers, and costs are mostly unknown.
One laboratory representative stated, “And it’s the complexities of the insurance system that
you know, we have to know every possible insurers policies or rules, for every patient in real time”.
Pharmacogenomic tests can be paid for by the insurer or the patient or absorbed by the laboratories
performing the testing as insurance policies vary. One laboratory representative stated, “I’ve definitely
had problems with of insurance either not covering it or requiring prior authorization”. A provider
stated, “I think more of an issue has been few patients who have had large bills sent to them because
they were told by the insurance they can only go to certain labs to get those tests done. That’s what I’ve
come across more than anything”. Another provider said, “the testing, it should be more transparent
and easier for the patient and the doctors to know whether a certain test is covered by a certain
insurer”. Laboratory representatives also reported that billing codes are unclear and open to different
interpretations, with one representative stating, “the molecular pathology billing landscape is very
bizarre . . . . Some people are interpreting it as, if my test has 5–50 genes, I bill the small panel code,
if my test has 51 or more, I bill the big panel code. Whereas other places are interpreting it as, if I’m
running a test of 300 genes, it doesn’t matter how many genes are on the test, if only four of them are
clinically relevant, or if only six of them are clinically relevant. So that’s the approach that our institute
has taken, only bill for the clinically relevant genes. So we run the same panel every time, it’s a panel
of—I don’t even know—300, 400, 500 genes, but it’s a lot of genes”.
Providers can adapt by using vendors who charge insurers so that the hospital or providers do
not receive a bill. Some laboratories have an appeals group who may reach out to the clinical team
for more clinical information in order to appeal to the insurer. Another laboratory is developing a
real-time adjudication process to let patients know how much their out of pocket costs would be as
“the computer can generate what the patient responsibility is”.
Interviewees offered several suggestions for improving the process of payment for
pharmacogenomic tests. Providers suggested making the forms easier to complete, and making
it obvious which form is needed. For example, one provider stated, “You know to be honest with you
in terms of prior authorization, that’s the biggest hindrance to be honest with you is that there’s no
standardization of the form. So most of the time when you’re trying to obtain a prior authorization,
it’s trying to figure out what form you need to submit”. Another laboratory representative stated that
although universal coverage documentation would be a potential solution, “it’s just a little complicated
figuring out what the right national policy would be”.
4. Discussion
Many pharmacogenomic tests are currently available and thousands are in the pipeline for
potential future use, yet little is known about their clinical implementation process. Our study
found that the clinical implementation process for pharmacogenomic tests is currently complex and
variable. Providers and laboratory representatives report many challenges to the process: the lack of
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standardized processes makes ordering confusing, ordering is time consuming, testing is expensive,
providers do not have expertise in using pharmacogenomics tests, and billing codes are nonspecific.
Recommendations proposed include making the process straightforward, making insurer policies
transparent, and developing clinical guidelines [15].
Some of the challenges in obtaining pharmacogenomic testing reported in our study have been
seen in previous studies. For instance, Miller et al. also reported that a major challenge to ordering
pharmacogenomic tests is that there is no set process for ordering the tests [16]. They also noted that
many providers reported that a lack of knowledge about how to order pharmacogenomic testing for
cancer was an important barrier [16]. Moreover, providers and laboratories in our study reported that
guidelines are needed on appropriate and relevant testing. Furthermore, laboratories in our study
felt an additional challenge is providers may not have the appropriate expertise to decide when to
order tests. While other studies support some of our results that providers lack confidence in this area,
our qualitative interviews allowed a broad exploration of additional challenges rather than being
limited to survey questions that were asked [16,17]. Providers and laboratory representatives in our
study identified additional challenges such as ordering pharmacogenomic tests is time-consuming,
there is great variability in insurance coverage, testing is expensive, clinical utility of tests is difficult
to assess, and ordering of panel tests is more complicated than single gene assays. Furthermore,
our study also highlights the complexity that the prior authorization process adds to the process.
Our findings that some providers lack the expertise to order the tests, and that health care
providers lack adequate training in genomics, especially given that staying on top of the latest
available genomic medicine tools, is a challenge are also consistent with prior research [1,18,19]
A study by Weldon et al. used qualitative interviews conducted from 2008 to 2009 that focused
on breast cancer pharmacogenomic tests concluded that major barriers to ordering the tests were
poor timing of testing relative to treatment decisions guided by the tests and obstacles related to
reimbursement [20]. Even though our study was several years later when more tests were available,
these same challenges remain.
Strengths of our study include that it focuses on examining the processes of ordering
pharmacogenomic tests from multiple viewpoints, i.e., providers, patients, and representatives of
diagnostic laboratories. Understanding such processes while there are already many cancer-related
pharmacogenomic tests being used—but prior to the tremendous influx of available tests—could
help guide use and payment of pharmacogenomic tests for a wide range of diseases. Despite the
strengths of our study, a few limitations deserve mention. First, our study is limited to patients who
are insured by Harvard Pilgrim Health Care and their providers and laboratories but we also included
commercial labs that serve other insurers and providers. Secondly, all the pharmacogenomic tests
were cancer-related and may not be generalizable to other pharmacogenomic tests. We focused on
cancer-related tests because they are being used in current clinical care. In addition, interviewing
insurers was beyond the scope of this study.
In summary, processes related to ordering and obtaining insurance coverage for pharmacogenomic
tests varies greatly across institutions and is time-consuming. Potential solutions include streamlining
the process for ordering tests, making reimbursement requirements by insurers transparent, developing
guidelines, and improving communication between providers, patients, and laboratories.
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